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Abstract
Background: Although the prevalence of macrolide-resistant Mycoplasma pneumoniae isolates in Japanese pediatric
patients has increased rapidly, there have been no reports concerning macrolide-resistant M. pneumoniae infection
in adolescents aged 16 to 19 years old. The purpose of this study was to clarify the prevalence and clinical
characteristics of macrolide-resistant M. pneumoniae in adolescent patients with community-acquired pneumonia.
Methods: A total of 99 cases with M. pneumoniae pneumonia confirmed by polymerase chain reaction (PCR) and culture
were analyzed. Forty-five cases were pediatric patients less than 16 years old, 26 cases were 16 to 19-year-old adolescent
patients and 28 cases were adult patients. Primers for domain V of 23S rRNA were used and DNA sequences of the PCR
products were compared with the sequence of an M. pneumoniae reference strain.
Results: Thirty of 45 pediatric patients (66%), 12 of 26 adolescent patients (46%) and seven of 28 adult patients (25%) with
M. pneumoniae pneumonia were found to be infected with macrolide-resistant M. pneumoniae (MR patients). Although
the prevalence of resistant strains was similar in pediatric patients between 2008 and 2011, an increase in the prevalence
of resistant strains was observed in adolescent patients. Among 30 pediatric MR patients, 26 had an A-to-G transition at
position 2063 (A2063G) and four had an A-to-G transition at position 2064 (A2064G). In 12 adolescent MR patients, 10
showed an A2063G transition and two showed an A2064G transition, and in seven adult MR patients, six showed an
A2063G transition and one showed an A2064G transition.
Conclusions: The prevalence of macrolide-resistant M. pneumoniae is high among adolescent patients as well as pediatric
patients less than 16-years old. To prevent outbreaks of M. pneumoniae infection, especially macrolide-resistant M.
pneumoniae, in closed populations including among families, in schools and in university students, physicians should pay
close attention to macrolide-resistant M. pneumoniae.
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Background
Mycoplasma pneumoniae is a common causative pathogen
of respiratory infections in children and adults, accounting
for as many as 10-30% of all cases of community-acquired
pneumonia (CAP) [1]. M. pneumoniae pneumonia is speci-
fied for weekly reporting by specially designated sentinel
clinics in accordance with the Japanese Infectious Diseases
Control Law. Between 2001 and 2010, the average number
of cases of M. pneumoniae pneumonia per sentinel clinic
per year was 16.2 [2]. In 2011, especially the second half of
the year, an epidemic of M. pneumoniae infection occurred
throughout Japan and the incidence was the highest
observed during the past decade, with the number of cases
per sentinel clinic reaching 36.3 per year [2]. Many out-
breaks of M. pneumoniae have occurred in closed popula-
tions including among families, in high schools, and in
university students. During 2010 and 2011, a similar surge
in M. pneumoniae infections was described in other coun-
tries especially in northern Europe [3-11].
Although M. pneumoniae pneumonia is usually mild in
severity, macrolide-resistant M. pneumoniae with mutations
in the 23S rRNA gene has emerged in pediatrics patients
with CAP [12,13]. Recently, the prevalence of macrolide-
resistant M. pneumoniae isolates in Japanese pediatric
patients has increased sharply [14]. More than 60% of M.
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pneumoniae strains in pediatric patients showed high
resistance to 14- and 15-membered ring macrolides with
MICs greater than or equal to 32 mg/L [14]. In contrast to
pediatric patients, the prevalence of macrolide-resistant M.
pneumoniae infection in adult patients is low [15]. Previous
reports were limited to pediatric patients less than 16 years
old or adults (≥20 years old), and there are no reports inves-
tigating high school-aged patients (16 to 18-years old)
[12,13,15-18]. Several studies to determine the influence of
age in CAP patients indicated that M. pneumoniae pneu-
monia is significantly more common in younger patients
and especially in the 10–20-year-old age group [1]. The pur-
pose of this study was to clarify the prevalence and clinical
characteristics of macrolide-resistant M. pneumoniae in
adolescents, especially high school-aged patients, with CAP.
Methods
Patients
This study was conducted as a part of CAP studies that
investigated the prevalence and clinical features of atypical
pneumonia and evaluated the usefulness of diagnostic
methods for the diagnosis of this condition. All patients
with CAP who visited 12 institutions participating in the
Atypical Pathogen Study Group from January 2008 to
December 2011 were enrolled in this study. The diagnosis
was based on clinical signs and symptoms of lower respira-
tory tract infection (cough, fever, productive sputum,
dyspnea, chest pain, or abnormal breath sounds) and the
presence of new infiltrates on chest radiographs that were
at least segmental and were not caused by preexisting or
other known causes. Informed consent was obtained from
all patients; the study protocol was approved by the Ethics
Committee at Kawasaki Medical School.
Microbiological laboratory tests
Microbiological tests, such as Gram stain, cultures, real-
time polymerase chain reaction (PCR), urinary antigen
tests and serological tests, were performed as described
previously [19]. Nasopharyngeal swab specimens were
obtained from all patients and, if pleural fluid and spu-
tum were available, a Gram stain test and a quantitative
culture were obtained. Blood cultures were obtained
from all adolescent and adult patients. Sputum data were
only evaluated when the Gram stain test revealed numerous
leukocytes (>25 in a×100 microscopic field) and few squa-
mous epithelial cells (<10 in a×100 microscopic field). Inva-
sive methods, such as bronchoscopic examination, were
employed to obtain specimens in some patients after full ex-
planation of the procedures. A bronchoscopic examination
was undertaken for clinical indications. These specimens were
also used for culturing and PCR. Cultures for M. pneumoniae
and Legionella species were performed on pleuropneumonia-
like organism broth (Difco, Detroit, MI, USA) and buffered
charcoal-yeast extract alpha agar, respectively. Cultures for
Chlamydophila pneumoniae and C. psittaci were performed
using cycloheximide-treated HEp-2 cells grown in a 24-well
cell culture plate. All specimens were examined twice. Culture
confirmation was done by fluorescent-antibody staining with
C. pneumoniae and C. psittaci species-specific and genus-
specific monoclonal antibodies. The target DNA sequences for
PCR were a region of the 53-kDa gene for C. pneumoniae, the
major outer membrane gene for Chlamydia, the P1 cytadhesin
gene for M. pneumoniae, and the nucleotide sequence of the
5S-ribosomal DNA for Legionella. DNA was extracted from
respiratory samples using a QIAamp DNAMini Kit (QIAGEN
K. K., Tokyo, Japan) in accordance with the manufacturer’s
instructions. The assays were performed as described
previously [19]. Nasopharyngeal swab specimens were also
tested for influenza A and B viruses by a direct enzyme
immunoassay.
Paired serum samples were collected at intervals of at
least 4 weeks after onset. Complement fixation (CF) tests
were done in all patients for antibodies to influenza A and
B viruses, adenovirus, respiratory syncytial virus, cyto-
megalovirus, and parainfluenza virus types 1, 2, and 3. Anti-
bodies against M. pneumoniae were measured with the use
of a particle agglutination (PA) test (Serodia-Myco II kit,
Fujirebio, Tokyo, Japan), Legionella species by a microagglu-
tination test (detection of L. pneumophila serogroups 1~6,
L. bozemanii, L. dumoffii, L. gormanii, and L. micdadei),
and Coxiella burnetii by an indirect immunofluorescence
test. A microimmunofluorescence test was used for the ti-
tration of IgG and IgM antibodies against chlamydial spe-
cies using formalinized elementary bodies of C. pneumoniae
KKpn-15, C. trachomatis L2/434/Bu, and C. psittaci
Budgerigar-1 strains as antigens. Rheumatoid factors were
absorbed with GullSORB (Meridian Bioscience Inc., OH,
USA) before IgM titration. In addition to serology,
culturing, and/or PCR, urinary antigen tests (Binax NOW,
Binax Inc. Portland, ME, USA) for S. pneumoniae and L.
pneumophila were performed in adolescent and adult
patients.
Criteria for the determination of microbial etiology
The microbial etiology was classified as "definitive", "pre-
sumptive", or "unknown" as reported previously [19]. A
definitive etiology was defined if one of the following
conditions was present: (1) blood or pleural fluid cultures
yielding the presence of bacterial or fungal pathogen; (2)
urinary antigen test results positive for L. pneumophila or S.
pneumoniae; (3) respiratory specimen culture or PCR
results positive for M. pneumoniae, C. psittaci or Legionella
species; (4) nasopharyngeal antigen test results positive for
influenza A and B viruses; (5) a fourfold increase in the anti-
body titer for viruses, M. pneumoniae (to ≥1:160),
Legionella species (to ≥1:128), C. burnetii, or Chlamydia
species (IgM or IgG); or (6) a single increase in IgM titer
for Chlamydia species ≥1:32. A presumptive etiology was
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considered if any of the following conditions were present:
(1) an organism showing heavy (≥107 cfu/mL) or moderate
(106 cfu/mL) growth of a predominant bacterium on a
sputum culture in combination with Gram stain findings;
(2) any microorganism isolated from bronchoscopic speci-
mens when its concentration reached ≥105 cfu/mL in
quantitative culture; (3) an antibody titer of ≥1:320 for M.
pneumoniae in either an acute-phase or convalescent-
phase serum sample; (4) an antibody titer of ≥1:256 for
Legionella species in either an acute-phase or convalescent-
phase serum sample; or (5) respiratory specimens culture
of PCR results positive for C. pneumoniae. An unknown
etiology was considered if any of the following conditions
were present: (1) respiratory specimens culture results were
“normal flora”; (2) an organism showing light growth on a
sputum culture; or (3) cases not fulfilling any of the above
conditions.
Detection of point mutations associated with resistance in
domain V of 23S rRNA
A search for mutations at sites 2063, 2064, and 2617 in the
M. pneumoniae 23S rRNA domain V gene region was per-
formed using a direct sequencing method in samples with a
positive PCR result, as reported previously [12,15,18]. Spe-
cifically, nested PCR was performed using a thermal cycler
(PCR Thermal Cycler Dice Gradient, Takara Bio, Inc., Shiga,
Japan) with primers (Sigma-Aldrich, Japan), Taq polymerase
(Takara Ex Taq Version; Takara Bio, Inc.), and extracted
DNA. The PCR products were purified using a QIAquick
PCR Purification Kit (QIAGEN). The purified products
were electrophoresed in a 3% Nusieve 3:1 agarose gel
(Lonza) and, after the single band was confirmed, labeled
using a BigDye Terminator V3.1 cycle sequencing kit
(Applied Biosystems) and applied to an ABI Prism 3130x1
Genetic Analyzer (Applied Biosystems) in accordance with
the manufacturer’s instructions. The presence or absence of
gene mutations at each site was determined by reading
using a sequence scanner (Applied Biosystems).
Minimum inhibitory concentrations
The minimum inhibitory concentrations (MICs) of three
agents for M. pneumoniae isolates were determined using
microdilution methods with PPLO broth, as reported
previously [12,15]. These agents were erythromycin, mino-
cycline, and levofloxacin. M. pneumoniae strain M129 was
used as a control. Serial twofold dilutions of antibiotics pre-
pared in PPLO broth containing 104 to 105 CFU/mL of M.
pneumoniae were placed in 96-well microplates [12,15].
The microplates were sealed with adhesive sheets and incu-
bated at 37°C. The MIC was determined as the lowest con-
centration of antimicrobial agent at which the color of the
control medium changed.
Statistical analysis
Statistical analysis was performed using Stat View version
5.0. (SAS Institute Inc, Cary, NC, USA). The incidence of
clinical findings was analyzed using Fisher's Exact test, and
laboratory data were compared using Student's t test.
Results
Prevalence of macrolide-resistant M. pneumoniae in
different age groups
During the study period, 1060 CAP cases were enrolled
in this study. A total of 423 cases were pediatric patients
less than 16 years old, 124 cases were 16 to 19-year-old
adolescent patients, and 513 cases were adult patients. A
microbiological diagnosis was established in 56% of
pediatric patients, 59% of adolescent patients, and 54%
of adult patients. The most common pathogens were M.
pneumoniae (23%) followed by Haemophilus influenzae
(15%) and S. pneumoniae (8%) in pediatric patients, M.
pneumoniae (29%) followed by S. pneumoniae (14%) and
H. influenzae (10%) in adolescent patients, and S.
pneumoniae (26%) followed by M. pneumoniae (10%)
and H. influenzae (7%) in adult patients.
Of all CAP cases, 99 cases were positive for M.
pneumoniae in culture and/or by the PCR method. Of
these, all cases were PCR positive, 40 cases were culture
positive and 85 cases demonstrated positive serological
results. No other microorganisms were detected in these
cases. Forty-five cases were pediatric patients, 26 cases
were adolescent patients and 28 cases were adult patients.
Thirty of 45 pediatric patients (66%), 12 of 26 ado-
lescent patients (46%), and seven of 28 adult patients
(25%) with M. pneumoniae pneumonia were found to
be infected with macrolide-resistant M. pneumoniae
(MR) patients. The prevalence of macrolide-resistant
M. pneumoniae in different age groups from 2008 to
2011 is presented in Figure 1. Among adolescent
patients, macrolide-resistant M. pneumoniae was iden-
tified in two of six patients in 2008, two of six
patients in 2009, two of four patients in 2010 and six
of 10 patients in 2011.
Patient characteristics
Table 1 shows the characteristics of MR and macrolide-
sensitive M. pneumoniae (MS) patients in different age
groups. As reported by Lucier et al. [20], Okazaki et al. [13],
and Morozumi et al. [14], an A-to-G transition or A-to-C
transversion at positions 2063 or 2064 in domain V on the
23 S rRNA gene results in resistance to macrolide antibio-
tics. Among 30 pediatric MR patients, 26 had an A-to-G
transition at position 2063 (A2063G) and four had an A-to-
G transition at position 2064 (A2064G). In 12 adolescent
MR patients, 10 showed an A2063G transition and two
showed an A2064G transition, and in seven adult MR
patients, six showed an A2063G transition and one showed
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an A2064G transition. No mutations at site 2617 in domain
V of the 23 S rRNA gene were observed. In terms of clinical
symptoms and laboratory findings, no significant differences
were observed between MR patients and MS patients in dif-
ferent age groups.
Minimum inhibitory concentrations
Twenty-two isolates of M. pneumoniae with a mutation of
the 23 S rRNA gene showed resistance to erythromycin
with a MIC of 128 to >128 mg/L (MIC90 of >128 mg/L),
whereas the other 18 isolates without a mutation of the
23 S rRNA gene showed susceptibility to erythromycin with
a MIC of 0.00195 to 0.0078 mg/L (MIC90 of 0.0078 mg/L).
The MICs for minocycline and levofloxacin for macrolide-
resistant isolates were equal to the MIC for susceptible iso-
lates at 0.25 to 2 mg/L (MIC90 of 1 mg/L) and 0.25 to
1 mg/L (MIC90 of 0.5 mg/L), respectively.
Discussion
Macrolides are generally considered to be the first-choice
agents for the treatment of M. pneumoniae infection.
Tetracyclines and fluoroquinolones are effective in the
treatment of M. pneumoniae infection, but the adminis-
tration of these agents to children is not recommended
because of their toxicity. Tetracyclines have the potential
to repress bone growth, cause permanent gray-brown
discoloration of the teeth, and enamel hypoplasia when
given during tooth development. The clinical importance
of fluoroquinolones has not been demonstrated because




















Figure 1 The prevalence of macrolide-resistant M. pneumoniae
in different age groups between 2008 and 2011. Although the
prevalence of resistant strains was similar in pediatric patients
between 2008 and 2011, an increase in the prevalence of resistant
strains was observed in adolescent patients. Shaded bar: pediatric
patients less than 16 years old, hatched bar: 16 to 19-year-old
adolescent patients, open bar: adult patients.
Table 1 Characteristics of patients with macrolide-resistant (MR) and macrolide-sensitive (MS) Mycoplasma pneumoniae
pneumonia in different age groups
Characteristic Pediatric patients Adolescent patients Adult patients
MR MS MR MS MR MS
Number 30 15 12 14 7 21
Age range, years 1–15 1–15 16–19 16–19 20–42 28–45
Male:female 16:14 7:8 6:6 8:6 4:3 11:10
Mutation site in 23S rRNA a
A2063G 26 10 6
A2064G 4 2 1
No. of patients prescribed macrolides (%) 23 (76) 15 (100) 9 (75) 9 (64) 5 (71) 6 (28)
Clarithromycin 12 10 5 4 2 2
Azithromycin 11 5 4 5 3 4
No. of patients with a change of prescription after macrolide
administration (%)
20 (66) 0 7 (58) 3 (21) 3 (42) 4 (19)
Minocycline 16 5 3 1 1
Quinolones 4 b 2 0 2 3
Clinical symptoms and laboratory findings at the first examination
Cough 30 15 12 14 7 21
Sputum 23 11 7 8 4 12
Fever, temperature ≥ 38°C 26 14 11 13 7 21
Respiratory rate, > 30/min 2 1 0 0 0 0
White Blood Cell, mean (/uL) 6,410 6,520 6,810 7,010 6,620 6,710
C-reactive protein, mean (mg/dL) 2.1 1.9 3.1 3.3 3.7 3.5
a A2063G: A-to-G transition at position 2063 in domain V on the 23S rRNA gene.
A2064G: A-to-G transition at position 2064.
b Tosufloxacin used.
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young animals. Thus, these agents should be avoided when
alternatives can be used. In contrast to pediatric patients,
fluoroquinolones and tetracyclines are usually administered
to adult patients with respiratory tract infections. These
agents demonstrate good clinical efficacy against macrolide-
resistant M. pneumoniae infection. Adolescent patients
usually visit a general physician not a pediatrician and
fluoroquinolones and tetracyclines may often be adminis-
tered against respiratory tract infections. General physicians
may readily treat respiratory infections using these agents in
adult and adolescent patients. Thus, the investigation of
macrolide-resistant M. pneumoniae infections has been
carried out only among the pediatricians in Japan.
In a previous study, we first reported macrolide-resistant
M. pneumoniae infections in adults (≥20 years old) in Japan
[15]. In the present study, the prevalence of macrolide-
resistant M. pneumoniae was similar between pediatric and
adolescent patients especially in 2011. Point mutations in
domain V of 23 S rRNA were also identical between these
two groups. Physicians should pay attention to macrolide-
resistant M. pneumoniae not only in children but also in
adolescent patients, especially those of high-school age.
In 2009, the first adult case of CAP caused by macrolide-
resistant M. pneumoniae was described in Japan [21]. We
have been investigating the prevalence of macrolide-
resistant M. pneumoniae in both children and adults since
2005, and we identified among adult patients, one of seven
patients in 2008, one of six patients in 2009, two of seven
patients in 2010, and three of eight patients in 2011 were
infected with macrolide-resistant M. pneumoniae [15].
Thus, the prevalence of macrolide-resistant M. pneumoniae
may be increasing in adult patients.
Macrolide-resistant M. pneumoniae is also emerging in
other several countries especially in children [5,22-26]. A
recent study in China has shown macrolide resistance in
69% of M. pneumoniae isolates from adolescent and
adult patients [26]. Thus, monitoring of M. pneumoniae
strains seems to be necessary in order to recognize early
changes in the antibiotic resistance pattern of this im-
portant agent of human respiratory tract infections.
Our study had limitations; we evaluated PCR-positive
patients (of these, 40 cases were culture positive). As
reported by several researchers, an A2063G transition and
an A2064G transition in domain V of the 23 S rRNA gene
resulted in resistance to macrolide antibiotics [13-15,20].
Among the 49 MR patients studied, 32 had A2063G and
seven had A2064G. Most of these isolates were highly re-
sistant to 14- and 15-membered ring macrolides with
MICs greater than or equal to 32 μg/mL [13-15,20]. Thus,
these data indicate that our PCR-positive patients with
point mutations at positions 2063 or 2064 in domain V on
the 23 S rRNA gene were resistant to macrolides. Further-
more, the number of patients characterized as adolescents
was very low to clarify the prevalence of resistance in this
age group. A large-scale surveillance study to investigate the
frequency of macrolide-resistant M. pneumoniae cases is
needed.
Conclusions
The prevalence of macrolide-resistant M. pneumoniae is
high among adolescent patients as well as pediatric
patients less than 16-years old. To prevent outbreaks of M.
pneumoniae infection, especially macrolide-resistant M.
pneumoniae, in closed populations including among
families, in schools, and in university students, physicians
should pay careful attention to the potential occurrence of
infections involving macrolide-resistant M. pneumoniae.
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